Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 689 |
| Number of pages | 1 |
| Journal | European Urology |
| Volume | 71 |
| Issue number | 4 |
| Early online date | 28 Dec 2016 |
| DOIs |
|
| Publication status | Published - 1 Apr 2017 |
Fingerprint
Cite this
Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease. / MacLennan, Steven; Briganti, Alberto; Grimshaw, Jeremy M; N'Dow, James.
In: European Urology, Vol. 71, No. 4, 01.04.2017, p. 689.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Words of Wisdom RE: Low adherence to guidelines in nonmuscle-invasive disease
AU - MacLennan, Steven
AU - Briganti, Alberto
AU - Grimshaw, Jeremy M
AU - N'Dow, James
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.
AB - The authors address the thorny issue of the lack of adherence to Clinical Practice Guidelines highlighting high-quality evidence based nonmuscle-invasive bladder cancer (NMIBC) guideline recommendations from the American Urological Association/Society of Urologic Oncology, and the European Association of Urology as exemplars [1]. In particular, they emphasise three strong practice recommendations underpinned by high-quality evidence: immediate intravesical installation of chemotherapy in patients with presumed low-risk or intermediate-risk NMIBC, the performance of a second transurethral resection for high-risk NMIBC, and the administration of adjuvant intravesical Bacillus Calmette–Guérin immunotherapy in high-risk NMIBC. Data from North America, Europe, and Australia are cited illustrating variability and general lack of adherence (ranging from 0.5% to 65%) to these recommendations.
U2 - 10.1016/j.eururo.2016.12.019
DO - 10.1016/j.eururo.2016.12.019
M3 - Comment/debate
VL - 71
SP - 689
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 4
ER -